Theranexus SA Asset Resilience Ratio
Theranexus SA asset resilience ratio. Theranexus SA (ALTHX) has an Asset Resilience Ratio of 66.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALTHX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Theranexus SA (2015–2025)
Asset resilience ratio of Theranexus SA from 2015 to 2025. This chart shows how Theranexus SA's Asset Resilience Ratio has changed over time. Read Theranexus SA debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Theranexus SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Theranexus SA balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.02 Million | 66.61% |
| Total Liquid Assets | €7.02 Million | 66.61% |
Asset Resilience Insights
- Very High Liquidity: Theranexus SA maintains exceptional liquid asset reserves at 66.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Theranexus SA Industry Peers by Asset Resilience Ratio
Compare Theranexus SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Theranexus SA Asset Resilience Ratio by Year (2015–2025)
Theranexus SA asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Theranexus SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.61% | €7.02 Million ≈ $8.21 Million |
€10.54 Million ≈ $12.33 Million |
+53.12pp |
| 2024-12-31 | 13.49% | €504.56K ≈ $589.88K |
€3.74 Million ≈ $4.37 Million |
-69.47pp |
| 2021-12-31 | 82.97% | €14.01 Million ≈ $16.38 Million |
€16.89 Million ≈ $19.75 Million |
+54.34pp |
| 2020-12-31 | 28.63% | €5.00 Million ≈ $5.85 Million |
€17.47 Million ≈ $20.42 Million |
-49.79pp |
| 2019-12-31 | 78.42% | €12.05 Million ≈ $14.09 Million |
€15.37 Million ≈ $17.97 Million |
-6.65pp |
| 2018-12-31 | 85.07% | €16.03 Million ≈ $18.75 Million |
€18.85 Million ≈ $22.04 Million |
+72.96pp |
| 2016-12-31 | 12.11% | €348.87K ≈ $407.86K |
€2.88 Million ≈ $3.37 Million |
-39.08pp |
| 2015-12-31 | 51.19% | €1.40 Million ≈ $1.63 Million |
€2.73 Million ≈ $3.19 Million |
-- |
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company… Read more